The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
11 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,494,939 in first-year total cost, median $324,935.
Most frequent study sections
- Special Emphasis Panel[ZRG1 SBIB-W (56)]11
Most frequent institutions
- WASHINGTON UNIVERSITY2
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE1
- DARTMOUTH COLLEGE1
- EMORY UNIVERSITY1
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2014 | Predictive MRI metrics for tumor aggressiveness in micropapillary thyroid cancer1R21CA176660-01A1 | DAVE, AMITA | SLOAN-KETTERING INST CAN RESEARCH, NY | $368,728 | ZRG1 |
| 2014 | Radiolabeled Trastuzumab to Improve Diagnosis and Staging of HER2+ Gastric Cancer1R21CA182965-01A1 | PARK, JINHA MARK | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $352,405 | ZRG1 |
| 2014 | PET/MR study of Metastatic Lymph Nodes in Head and Neck Cancer1R21CA188217-01 | KIM, SUNGHEON GENE | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $351,713 | ZRG1 |
| 2014 | Improving extent of glioblastoma resection by combining volumetric MRSI and 5-ALA1R21CA186169-01 | HADJIPANAYIS, CONSTANTINOS GEORGEHOLDER, CHAD A.MAUDSLEY, ANDREW A.SHIM, HYUNSUK | EMORY UNIVERSITY, GA | $336,932 | ZRG1 |
| 2014 | Tumor mutation status will predict metabolic response to metformin in NSCLC1R21CA182964-01A1 | GUERRERO, THOMAS MSKINNER, HEATH DEVIN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $332,000 | ZRG1 |
| 2014 | A Phase I Study of CED of Liposomal-Irinotecan using imaging in High Grade Glioma1R21CA186140-01 | BUTOWSKI, NICHOLAS A | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $324,935 | ZRG1 |
| 2014 | Image-Guided Surgery in Non-palpable Breast Cancer with Coregistered Supine MR1R21CA182956-01A1 | BARTH, RICHARD | DARTMOUTH COLLEGE, NH | $323,173 | ZRG1 |
| 2014 | EVALUATION OF POSITRON EMISSION TOMOGRAPHY-MAGNETIC RESONANCE IMAGING (PET-MRI)1R21CA179541-01A1 | FIELDS, RYAN C | WASHINGTON UNIVERSITY, MO | $315,400 | ZRG1 |
| 2014 | A FEASIBILITY PET STUDY OF HER2 RECEPTORS IN BREAST CANCER USING 89ZR-TRASTUZUMAB1R21CA182945-01 | DEHDASHTI, FARROKH | WASHINGTON UNIVERSITY, MO | $315,400 | ZRG1 |
| 2014 | Imaging Guided Surgery using Fluorescently Labeled Cetuximab1R21CA182953-01A1 | ROSENTHAL, EBEN L. | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $268,136 | ZRG1 |
| 2014 | Multi-Tracer PET/CT Imaging of Gemcitabine Response in Pancreatic Cancer1R21CA182977-01A1 | GARRIDO-LAGUNA, IGNACIOKADRMAS, DAN J | UNIVERSITY OF UTAH, UT | $206,117 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.